Boston Scientific is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 5 active Congressional signals mentioning Boston Scientific, including 5 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
Boston Scientific ($BSX) is currently facing 5 active congressional signals tracked by HillSignal. With 4 bullish, and 1 bearish signals, the average legislative impact score is 4.8/10. Key sectors affected include Healthcare, Manufacturing and Finance. Recent major catalysts include HEAR Act of 2025 and Pandemic and All-Hazards Preparedness Reauthorization Act of 2013. Below is the complete tracker of government activity affecting Boston Scientific’s market performance.
The Veterans Prosthetics Advancement and Reform Act, S2981, establishes a formulary for prosthetic and rehabilitative items and services within the VA, ensuring increased and standardized procurement. This guarantees a stable and growing market for medical device manufacturers specializing in prosthetics and rehabilitation technologies. Companies like Zimmer Biomet Holdings ($ZBH) and Stryker ($SYK) directly benefit from this expanded and formalized VA procurement process.
Impact: 4/10(Early stage (action not classified))S2981Congressional Bill
The HEAR Act of 2025 mandates Medicare coverage for hearing aids and related rehabilitation services, directly expanding the market for hearing device manufacturers and audiology service providers. This legislation creates a new revenue stream for companies in the hearing health sector by bringing Medicare beneficiaries into the market.
Impact: 6/10(Committee action)HR6218Congressional Bill
The Amputation Reduction and Compassion Act of 2025 (ARC Act of 2025) mandates Medicare and Medicaid coverage for peripheral artery disease (PAD) screening tests without cost-sharing for at-risk individuals. This directly increases demand for PAD diagnostic services and devices, benefiting medical device manufacturers and diagnostic laboratories. The bill also requires educational programs and a payment model to reduce amputations.
Impact: 5/10(Early stage (action not classified))HR307Congressional Bill
The Putting Patients First Healthcare Freedom Act dismantles key Affordable Care Act provisions, directly reducing revenue for large health insurers and healthcare providers. This shift benefits Health Savings Account (HSA) providers and Health Care Sharing Ministries by expanding their market and utility. The bill eliminates enhanced ACA subsidies, impacting the financial stability of the current healthcare ecosystem.
Impact: 5/10(Early stage (action not classified))HR6512Congressional Bill
Ellie's Law mandates increased comprehensive research at the National Institute of Neurological Disorders and Stroke (NINDS) on unruptured intracranial aneurysms. This directs federal funding towards research, diagnostics, and treatment development for brain aneurysms. Companies involved in neurological diagnostics, medical devices, and research services will benefit.